Autologous bone marrow transplant (ABMT) and stem cell transplantation (ASCT) are important treatment modalities for @entity3052 ( @entity3052 ). The role of ASCT in first remission @entity1 remains controversial. Phase II and phase III studies demonstrate that @entity1 with favorable-risk cytogenetics benefit from ASCT, with reduction in relapse and improvement in @entity1778 -free survival (LFS). @entity1 with poor-risk cytogenetics do not appear to benefit significantly from ASCT and should preferentially be treated with allogeneic transplant. The role of ASCT for @entity1 with intermediate risk disease is uncertain. It appears that ASCT in first remission will improve disease-free survival compared to standard chemotherapy. Sufficient @entity1 who relapse after chemotherapy treatment can be salvaged with ASCT in second remission such that the beneficial effect on overall survival is blunted. ASCT produces equivalent results to ABMT but with reduced morbidity. The collection of stem cells during recovery from intensive dose consolidation therapy appears to be an attractive strategy that can increase the percentage of @entity1 who are able to receive their intended transplant. Consolidation therapy prior to stem cell collection and transplant has been shown to decrease the relapse rate and improve outcomes, but the optimal nature of this consolidation therapy is unknown. For @entity1 with @entity3052 in second remission, ABMT/ASCT offers a substantial salvage rate, and is particularly effective for @entity1 with @entity2799 .

Autologous stem cell transplantation for XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity2799 :: ('MESH:D015473', 'Disease') :: ['acute promyelocytic leukemia'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
